Privacy Regulations Paradox
Regulations designed to protect consumers’ privacy can have unintended, negative consequences.
Regulations designed to protect consumers’ privacy can have unintended, negative consequences.
This ARF Pharma Council event followed up on the Council’s podcast episode on “Inclusive Futures of Humancare,” focusing on the importance of inclusiveness in pharma research and marketing with respect to both demographic characteristics and health conditions. Four speakers delivered brief presentations, followed by a discussion moderated by Pharma Council Co-Chair Marjorie Reedy of Merck.
David Kingsbury reviewed data from his 2019 ARF AUDIENCExSCIENCE presentation, and IRI’s subsequent advances to improve accessibility, targeting, and measurement of the digital invisible. This research has helped uncover a sliver of those invisible, i.e., households that move and are lost (either temporarily or permanently).
Research during the summer of 2021 revealed that the demographics of the digital invisible remained the same. Digital invisible consumers are more likely to skew low income, no kids, and under 34 years of age. They are part of the 13% of the population who move annually. Additionally, some consumers don’t want to be tracked. This population is not receiving targeted advertising and their purchases are not being measured.
This ARF Pharma Council event followed up on the Council’s podcast episode on “Inclusive Futures of Humancare,” focusing on the importance of inclusiveness in pharma research and marketing with respect to both demographic characteristics and health conditions. Four speakers delivered brief presentations, followed by a discussion moderated by Pharma Council Co-Chair Marjorie Reedy of Merck.
This ARF Pharma Council event followed up on the Council’s podcast episode on “Inclusive Futures of Humancare,” focusing on the importance of inclusiveness in pharma research and marketing with respect to both demographic characteristics and health conditions. Four speakers delivered brief presentations, followed by a discussion moderated by Pharma Council Co-Chair Marjorie Reedy of Merck.
Member Only Access